In the latest close session, CRISPR Therapeutics AG (CRSP) was down 5.44% at $49.93. This move lagged the S&P 500's daily loss of 0.08%. On the other hand, the Dow registered a loss of 0.61%, and the ...

This article looks at the ARK Invest Stock Portfolio: Top 10 Stock Picks for 2026. ARK Investment Management LLC, or ARK Invest, is an American investment management firm that oversees several ...

BERKELEY, Calif., March 05, 2026 (GLOBE NEWSWIRE) -- Caribou Biosciences, Inc. (Nasdaq: CRBU), a leading clinical-stage CRISPR genome-editing biopharmaceutical company, today reported financial ...

Current shareholders were thrown an unexpected curveball that they actually should have been expecting.

ARK Invest purchased ~281K CRISPR Therapeutics (CRSP) shares worth $14.82M after a 10% drop triggered by a $350M private offering announcement.

CRISPR Therapeutics (NASDAQ:CRSP) is one of the best stocks for 20 years. On February 12, CRISPR Therapeutics announced its financial results for 2025, highlighting a period of significant commercial ...

CRISPR Therapeutics (CRSP) upsized a $550M convertible notes deal due 2031 at 1.125%, with a 45% conversion premium—get the key terms now.

Cathie Wood’s ARK Invest added to several beaten-down technology and biotech names while trimming positions elsewhere. The investment manager made a notable purchase in gene-editing company CRISPR ...

CRISPR Therapeutics AG (NASDAQ:CRSP) is among the ARK Invest Stock Portfolio: Top 10 Stock Picks for 2026, with a stake value ...

Shares of Crispr Therapeutics were lower after the company said it would raise $350 million through a private offering of senior notes. The stock was down 7.3% at $54.49 in Tuesday morning trading.

Detailed price information for Chipmos Tech ADR (IMOS-Q) from The Globe and Mail including charting and trades.

Detailed price information for Chipmos Tech ADR (IMOS-Q) from The Globe and Mail including charting and trades.